Absorption: Well absorbed from PO dosage forms; absorption from extended-release dosage forms is slow but complete. IV administration results in complete bioavailability.
Distribution: Widely distributed; does not distribute into adipose tissue.
Half-Life: Premature infants: 2030 hr; Term infants: 1125 hr; Children 14 yr: 3.4 hr; Children 617 yr: 3.7 hr; Adults: 910 hr (↑ in patients >60 yr, patients with HF or liver disease; ↓ in cigarette smokers ).
(bronchodilation)
ROUTE | ONSET‡ | PEAK | DURATION |
---|---|---|---|
PO | rapid | 12 hr | 6 hr |
PO-ER | delayed | 48 hr | 824 hr |
IV | rapid | end of infusion | 68 hr |
‡Provided that a loading dose has been given and steady-state blood levels exist.
Contraindicated in:
Use Cautiously in:
CV: tachycardia, angina, ARRHYTHMIAS, palpitations
GI: nausea, vomiting, anorexia
Neuro: anxiety, headache, insomnia, irritability, SEIZURES, tremor
Drug-drug:
Drug-Natural Products:
Lab Test Considerations:
Toxicity and Overdose:
IV Administration: